TVI Pancreas 1
Alternative Names: TVI-Pancreas-1Latest Information Update: 12 Oct 2023
Price :
$50 *
At a glance
- Originator TVAX Biomedical
- Class Antineoplastics; Cancer vaccines; Immunotherapies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 10 Oct 2023 TVI Pancreas 1 is still in preclinical development for pancreatic cancer in USA (TVAX Biomedical pipeline, October 2023)
- 10 Oct 2023 TVAX Biomedical plans a phase II trial for pacreatic cancer (TVAX Biomedical pipeline, October 2023)
- 28 Dec 2022 No recent reports of development identified for preclinical development in Pancreatic-cancer in USA (IV, Infusion)